Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Fibrosis 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 9Specimen Handling 7Sorafenib 7Erlotinib Hydrochloride 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Fluorouracil 5Thalidomide 4Radiofrequency Ablation 4Bevacizumab 4tremelimumab 3cediranib 3cabozantinib 3Trastuzumab 3Pharmacogenomic Testing 3Nivolumab 3Neoadjuvant Therapy 3Melphalan 3MK 2206 3Irinotecan 3Fluorodeoxyglucose F18 3Dasatinib 3Cisplatin 3Chemotherapy, Adjuvant 3Bortezomib 3Biopsy 3AZD 6244 3trametinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Hepatocellular × Simvastatin × Clear all
NCT02968810 2026-05-29

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

National Cancer Institute (NCI)

Phase 2 Active not recruiting
52 enrolled 15 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡